<DOC>
	<DOCNO>NCT00583622</DOCNO>
	<brief_summary>The goal clinical research study learn bevacizumab , give combination gemcitabine , docetaxel , melphalan carboplatin , topotecan , cyclophosphamide melphalan ( old 60 allergy carboplatin ) , help control ovarian cancer stem cell transplant . The safety drug combination also study .</brief_summary>
	<brief_title>Bevacizumab Plus Gemcitabine , Docetaxel , Melphalan , Carboplatin Ovarian Cancer Patients</brief_title>
	<detailed_description>The Study Drugs : Bevacizumab design prevent slow growth cancer cell block growth blood vessel . Carboplatin design damage DNA ( genetic material ) cancer cell , may cause die . Melphalan design damage DNA cell , may cause cancer cell die . Docetaxel design stop growth cancer cell , may cause cell die . Gemcitabine design disrupt growth cancer cell , may cause cancer cell die . It may also help docetaxel , carboplatin , melphalan effective stop tumor cell repair damage cause drug . Topotecan design damage DNA cell , may cause cancer cell die . Cyclophosphamide design damage DNA cell , may cause cancer cell die . Stem Cell Removal : Before begin receive study drug , apheresis do collect stem cell part standard care . Apheresis process remove part blood ( platelet white blood cell ) body order remove certain element , stem cell . Then , rest blood return back body . Apheresis do central venous catheter ( CVC ) , usually chest . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form procedure . Your stem cell put back body finish receiving gemcitabine , docetaxel , melphalan , carboplatin . To prevent clotting , citrate ( blood thinner ) add CVC apheresis procedure . Study Drug Administration : If find eligible take part study , 2 week admission hospital ( 3 week stem cell transplant ) , receive bevacizumab CVC 45 minute . On Day 1 stay hospital , receive bevacizumab CVC 45 minute . As part standard mouth care , ask mouthwash 4 time day ( 2 minute time ) caphosol ( artificial saliva ) follow glutamine . Fifteen ( 15 ) minute caphosol mouthwash , swish glutamine around mouth gargle 2 minute , spit . Do swallow . On Day 2 , CVC , receive gemcitabine 3 hour docetaxel 2 hour . If allergic carboplatin old 60 receive topotecan 30 minute . On Day 3-5 , CVC , receive gemcitabine 3 hour , melphalan 15 minute , carboplatin 2 hour . On Day 6 , receive study drug . On Day 7 , receive stem cell CVC 30-60 minute . Starting day stem cell transplant , part standard care , receive granulocyte-colony stimulate factor ( G-CSF filgrastim ) injection skin daily , start 1 day transplant , blood cell level return normal . Starting 2 day transplant 10 day transplant , receive methylprednisolone 2 time day . If allergic carboplatin old 60 : On Day 1 stay hospital , receive bevacizumab CVC 45 minute . On Day 2-4 , CVC , receive cyclophosphamide 2 hour topotecan 30 minute . Each time receive cyclophosphamide , also receive mesna decrease risk bleed bladder . On Day 5-6 , CVC , receive melphalan 30 minute topotecan 30 minute . On Day 7 , receive study drug . On Day 8 , receive stem cell CVC 30-60 minute . Starting day stem cell transplant , part standard care , receive G-CSF ( filgrastim ) injection skin daily , start 1 day transplant , blood cell level return normal . Study Visits : At least week transplant , 30 , 60 , 100 day stem cell transplant , follow test procedure perform : - Your medical history record . - You physical exam . - You check possible reaction treatment , include graft-versus-host disease ( GVHD ) graft failure . Graft failure occur donor cell may able grow multiply body . If happens , high risk infection and/or bleed . - Blood ( 3 tablespoon ) draw routine test check tumor marker check status disease . - Urine collect routine test . - You pelvic exam , doctor think need . - You ECHO , doctor think need . - You lung function test , doctor think need . - You CT scan chest , abdomen , pelvis check status disease , doctor think need . - You positron emission tomography - compute tomography ( PET-CT ) scan check status disease . A PET-CT CT scan take small amount radioactive glucose ( sugar ) inject vein find cancer cell body . These test procedure may perform often , doctor think need . End-of-Treatment Visit : About 6 12 month stem cell transplant , year ( doctor think need ) , study visit test procedure list repeat . Length Study : You study 6 month . You take study early disease get bad , enough stem cell collect , experience intolerable side effect . Long-Term Follow-up : If doctor think necessary , may follow-up visit . This investigational study . Bevacizumab FDA approve commercially available treatment colorectal cancer . Gemcitabine , docetaxel , melphalan , carboplatin FDA-approved commercially available treatment ovarian cancer . The use bevacizumab gemcitabine , docetaxel , melphalan , carboplatin investigational . Up 30 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Age 18 &lt; 70 . 2 . Patients advanced ovarian , fallopian primary peritoneal cancer second later complete remission , untreated refractory relapse , define relapse within 6 month prior platinum treatment lack response salvage treatment . 3 . No evidence small bowel obstruction , determine CT scan abdomen pelvis oral rectal contrast , within 30 day initiation study treatment . 4 . Adequate renal glomerular tubular function , define estimate serum creatinine clearance &gt; =60 ml/min , urinary protein excretion &lt; =500 mg/day . 5 . Adequate hepatic function , define serum glutamic oxaloacetic transaminase ( SGOT ) , serum glutamic pyruvic transaminase ( SGPT ) &lt; =3 * upper limit normal ( ULN ) ; serum bilirubin alkaline phosphatase &lt; =2 * ULN consider clinically significant . 6 . Adequate pulmonary function Forced expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) Carbon Monoxide Diffusing Capacity ( DLCO ) &gt; =50 % predict , correct volume hemoglobin . 7 . Adequate cardiac function leave ventricular ejection fraction &gt; =45 % . No uncontrolled arrhythmias symptomatic cardiac disease . 8 . Zubrod performance status &lt; 2 . 1 . Failure collect 3 * 10e6 CD34+ stem cells/kg body weight 2 . Patients unresolved grade 3 great nonhematologic toxicity previous therapy . Patients grade 2 toxicity eligible discretion principal investigator . 3 . Major surgery within 30 day initiation study treatment 4 . Radiotherapy within 21 day prior initiation study treatment 5 . Patients active Central Nervous System ( CNS ) disease . 6 . Evidence acute chronic active hepatitis cirrhosis . If positive hepatitis serology , discus Principal Investigator consider liver biopsy . 7 . Uncontrolled infection , include HIV HTLV1 infection . 8 . Aspirin ( &gt; 325 mg/day ) use within 10 day initiation study treatment . 9 . Ongoing uncontrolled hypertension ( &gt; 140/90 mm Hg medication ) . 10 . Nonhealing wound significant traumatic injury within 30 day initiation study treatment 11 . Previous autologous allogeneic stem cell transplant past year . 12 . Positive Beta HCG test woman childbearing potential , define postmenopausal 12 month previous surgical sterilization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Epithelial Ovarian Cancer</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Carboplatin</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Melphalan</keyword>
</DOC>